Related Experiment Videos
The beta 2-adrenergic agonist terbutaline suppresses acute passive transfer experimental autoimmune myasthenia gravis
E Chelmicka-Schorr1, R L Wollmann, M N Kwasniewski
1Department of Neurology, University of Chicago, IL 60637.
International Journal of Immunopharmacology
|January 1, 1993
Abstract:
Treatment of Lewis rats with the beta 2-adrenergic agonist terbutaline suppressed clinical symptoms of acute passive transfer EAMG induced with monoclonal anti-acetylcholine receptor antibody and accelerated clinical recovery in affected animals. Electrophysiological studies showed that the amplitude of the first compound muscle action potential was significantly larger in terbutaline-treated rats as compared to controls. In both groups, a comparable number of inflammatory cells at the muscle endplates was seen.